Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non‐small‐cell lung cancer by high‐performance liquid chromatography‐tandem mass spectrometry
- 17 October 2007
- journal article
- research article
- Published by Wiley in Journal of Mass Spectrometry
- Vol. 43 (2) , 216-223
Abstract
Gemcitabine, 2′,2′‐difluoro‐2′‐deoxycytidine (dFdC) is a pyrimidine antimetabolite employed against several human malignancies. It undergoes intracellular activation to the pharmacologically active triphosphate form (dFdCTP) and metabolic inactivation to the metabolite 2′,2′‐difluorodeoxyuridine (dFdU). In order to investigate the human plasma pharmacokinetics of dFdC and dFdU, we developed and validated an HPLC‐MS/MS method, adding 2′‐deoxycytidine as internal standard and simply precipitating the protein with acetonitrile. The method requires a small sample (125 µl), and it is rapid and selective, allowing good resolution of peaks from the plasma matrix in only 7 min. It is sensitive, precise and accurate, with overall precision, expressed as CV%, always less than 10.0% for both analytes and high recovery: ≥ 80%. The limits of detection for dFdC and dFdU were 0.1 and 1.1 ng/ml, but considering the high concentrations in the plasma of patients investigated, we set the limit of quantitation at 20 ng/ml (0.08 µM) for dFdC and 250 ng/ml for dFdU, and validated the assay up to the dFdC concentration of 6.0 µg/ml (22.8 µM). The method was successfully used to study the drug pharmacokinetics in patients with advanced non‐small‐cell lung cancer in a phase II trial with gemcitabine administered as a fixed dose‐rate infusion. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 18 references indexed in Scilit:
- A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patientsAnnals of Oncology, 2006
- Systemic chemotherapy in locally advanced and/or metastatic bladder cancerCancer Treatment Reviews, 2006
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic CancerJournal of Clinical Oncology, 2006
- Overview of Gemcitabine Activity in Advanced Breast CancerSeminars in Oncology, 2006
- Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975Journal of Clinical Oncology, 2003
- Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2003
- Clinical Pharmacokinetics of Nucleoside AnaloguesClinical Pharmacokinetics, 2000
- Novel chemotherapeutic agents in clinical developmentCurrent Opinion in Oncology, 1991
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991
- Saturation of 2?, 2?-difluorodeoxycytidine 5?-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabineCancer Chemotherapy and Pharmacology, 1991